Intensified Follow-up of Lung Cancer Using Weekly Questionnaires Via the Internet

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

494 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-18

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled trial (RCT) will test if weekly supplementary internet-based self-monitoring of 12 core symptoms can increase survival in Danish lung cancer patients during follow-up or maintenance treatment. A threshold mechanism will automatically send an alert to the hospital in case of alarming or worsening symptoms and the patient will be contacted by the treating clinicians.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients

NCT03529851

Lung Cancer Stage IV

COMPLETED NA

Navigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients

NCT05053997

Lung Cancer

RECRUITING NA

Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

NCT03740126

Carcinoma, Non-Small-Cell Lung

ACTIVE_NOT_RECRUITING NA

Randomized Study of Positron Emission Tomography - Computed Tomography (PET/CT) in Pre-Operative Staging of Lung Cancer

NCT00867412

Non-Small Cell Lung Cancer Thoracotomy

COMPLETED

Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer

NCT06244355

Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicenter RCT study enrolls patients diagnosed with stage IV og incurable stage III lung cancer who has non-progressive disease at first evaluation scan. Patients in follow-up or maintenance therapy are eligible.

492 patients will be included in the study with 246 patients in each group.

Intervention In the experimental arm, patients will be asked to fill in a web-based Patient Reported Outcome (PRO) questionnaire every week. If one of the reported symptoms worsens and exceed a predefined threshold of severity, a notification is automatically sent to the hospital. A nurse will review til questionnaire and contact the patient for verification of symptoms. If progression of disease is suspected, a CT scan will be made. Otherwise, the nurse will schedule a visit at the clinic for physical examination and evaluation by a clinician. If progressive disease is not suspected, supportive care will be adjusted and the patient will continue follow up according to the usual schedule.

The interventions ends in case of progressive disease.

Evaluation Baseline CT-scan of thorax and upper abdomen is performed prior to initial treatment and an evaluation CT scan at the time of enrolment. CT scans will be repeated for assessing signs of progression due to standard follow-up procedures in both groups. If progressive disease is suspected based on symptom development, the following scan will be rescheduled to as soon as possible.

Quality of life (QoL) will be measured in both groups using EORTC (European Organisation for Research and Treatment of Cancer) QOL-C30 / LC13 and HADS (Hospital Anxiety And Depression Scale) quality of life questionnaires every 2 month during the study period.

Objectives The primary objective is to test if supplementary weekly PRO monitoring increases overall survival in a Danish Lung Cancer population

Monitoring Clinical decisions taken on the basis of PRO notifications will daily be registered in the software system by the clinicians. Patient responses to questionnaires and PRO-notification handling by the clinical staff will be monitored by Primary Investigator.

End points will be entered by local site investigators.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The randomization will be done by the AmbuFlex-system (a generic on-line system for self-recorded patient reported outcomes) as a part of the inclusion process.

A text message reminder is sent weekly for patients in the intervention group by the system.

Quality of Life questionnaires will automatically be sent via a safe internet connection to participants in both groups every 2 months.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRO intervention

Weekly PRO questionnaires Quality of life every 2 months

Group Type EXPERIMENTAL

Weekly Internet based PRO questionnaires

Intervention Type OTHER

If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.

Standard of care

Quality of life every 2 months

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Weekly Internet based PRO questionnaires

If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with lung cancer (NSCLC and SCLC), who have received 1st line induction treatment\* for lung cancer and have no sign of progressive disease at first evaluation CT scan.
2. Patients diagnosed with stage III treated with palliative intention, and stage IV, regardless of treatment intention.
3. Diagnosis proven by cytology or histology
4. Age ≥ 18 years
5. Performance status (PS) ≤ 2 within 15 days before enrolment
6. First evaluation CT scan performed within four weeks from enrolment
7. Patient with acess to internet, Mobile phone and E-boks (Danish digital secure mail system)
8. Patient has given his/her written informed consent before any specific procedure from protocol

* Induction treatment includes:

* Standard doublet chemotherapy
* Immunotherapy
* Targeted therapy
* Palliative radiotherapy
* Local treatment of oligometastatic disease, including surgery and stereotactic radiotherapy
* Any combination of the above-mentioned treatment modalities Patients are eligible regardless of whether they at the time of inclusion continue maintenance treatment or not

Exclusion Criteria

1. Progressive disease at first evaluation scan
2. Persons deprived of liberty or under guardianship or curators
3. Dementia, mental alteration or psychiatric disease that can compromise informed consent from the patient and / or adherence to the protocol and the monitoring of the trial
4. Pregnant or breastfeeding women
5. Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol committee.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No